Core Insights - Junshi Bioscience's stock increased by 0.72% on October 24, with a trading volume of 274 million yuan, indicating active market participation [1] - The company reported a financing net buy of -4.67 million yuan on the same day, suggesting a higher level of selling pressure compared to buying [1] - As of October 24, the total margin balance for Junshi Bioscience reached 1.39 billion yuan, indicating a high level of leverage in the market [1] Financing and Margin Data - On October 24, Junshi Bioscience had a financing buy amount of 27.26 million yuan, with a current financing balance of 1.378 billion yuan, accounting for 4.76% of its market capitalization [1] - The financing balance is above the 90th percentile of the past year, indicating a high level of borrowing [1] - In terms of securities lending, 941 shares were repaid while 700 shares were sold, with a selling amount of 26,400 yuan, and the remaining securities lending balance was 1.219 million yuan, also above the 90th percentile of the past year [1] Company Overview - Junshi Bioscience, established on December 27, 2012, focuses on the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs [2] - The company's main revenue sources include 90.67% from drug sales, 8.74% from technology licensing, and 0.59% from technical services [2] - As of June 30, 2025, the company reported a revenue of 1.168 billion yuan, a year-on-year increase of 48.64%, while the net profit attributable to shareholders was -413 million yuan, reflecting a 36.01% increase [2] Shareholder Structure - As of June 30, 2025, Junshi Bioscience had 31,200 shareholders, an increase of 5.88% from the previous period [2] - The average number of circulating shares per shareholder decreased by 5.56% to 24,543 shares [2] - Major shareholders include Huaxia SSE STAR 50 ETF and E Fund SSE STAR 50 ETF, with notable changes in their holdings [3]